Luma Group closes debut life sciences fund at $410M
What's the deal? Luma GroupDealroom has a profile for this one. Try Dealroom →, a New York-based investment firm, has closed its inaugural life sciences venture fund, LumaBio Fund I, with $410 million in committed capital. The fund drew a global investor base spanning financial institutions, sovereign wealth funds, insurance companies, family offices, and ultra-high-net-worth individuals.
What's the endgame? Structured as a 15-year vehicle, the fund invests early alongside founders and backs its highest-conviction companies from discovery to commercialisation. The firm is built on the conviction that the convergence of biology, chemistry, physics, and artificial intelligence will reshape medicine.
The track record: Since 2023, LumaBio Fund I has invested in Aeovian Pharmaceuticals, Altos Labs, Arsenal BiosciencesDealroom has a profile for this one. Try Dealroom →, Character Biosciences, and several others still in stealth. Earlier this year, it logged its first exit when Eli LillyDealroom has a profile for this one. Try Dealroom → acquired Vaccine Company in a deal valued at up to $1.55 billion.
What they said: "This Fund represents more than capital — it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines," said founder and managing member Joshua Fink.
The signal: Luma Group's long-dated structure and AI-informed strategy reflect a broader bet that patient capital, paired with computational tools, can accelerate drug discovery. Its early exit gives the debut fund a proof point rarely available at first close.
Image credit: Luma Group
